| Texto completo | |
| Autor(es): |
Moraes, Julio C. B.
[1]
;
Ribeiro, Ana C. M.
[1]
;
Saad, Carla G. S.
[1]
;
Lianza, Alessandro C.
[2]
;
Silva, Clovis A.
[1]
;
Bonfa, Eloisa
[1]
Número total de Autores: 6
|
| Afiliação do(s) autor(es): | [1] Univ Sao Paulo, Fac Med, Div Rheumatol, BR-01246903 Sao Paulo - Brazil
[2] Univ Sao Paulo, Fac Med, Div Radiol, BR-01246903 Sao Paulo - Brazil
Número total de Afiliações: 2
|
| Tipo de documento: | Artigo Científico |
| Fonte: | CLINICAL RHEUMATOLOGY; v. 32, n. 6, p. 879-883, JUN 2013. |
| Citações Web of Science: | 10 |
| Resumo | |
N-terminal pro-brain natriuretic peptide (NT-proBNP) is a strong marker of cardiovascular disease with recent evidence that inflammation may also influence its levels; discrimination of this confounding variable is of particular interest in rheumatic diseases. Therefore, we evaluated NT-proBNP in ankylosing spondylitis (AS) patients pre- and post-TNF blocker to determine the possible association between NT-proBNP levels and inflammatory parameters. Forty-five consecutive AS patients without previous/current cardiovascular disease or systolic myocardial dysfunction, who were eligible to anti-TNF therapy, were prospectively enrolled. All patients received TNF blockers and they were evaluated for circulating NT-proBNP levels, clinical and laboratory parameters of disease activity, traditional cardiovascular risk factors, and conventional and tissue Doppler imaging echocardiography at baseline (BL) and 6 months after (6M) treatment. At BL, all patients had active AS, NT-proBNP levels had a median of 36 (20-72) pg/mL and 11 % were high in spite of no systolic alteration. Multiple linear regression analysis revealed that this peptide, at BL, was independently correlated with erythrocyte sedimentation rate (ESR) (p < 0.001), age (p = 0.01), and pulse pressure (p = 0.01). After 6M, all disease parameters improved and NT-proBNP levels were significantly reduced {[}24 (16-47) pg/mL, p = 0.037] compared to BL. Changes in NT-proBNP were positively correlated with ESR changes (r = 0.41, p = 0.006). Cardiovascular risk factors remained stable during follow-up. In conclusion, our data suggest that elevations of NT-proBNP should be interpreted with caution in active AS patients with no other evidence of cardiovascular disease. The short-term reduction of NT-proBNP levels in these patients receiving anti-TNF therapy appears to reflect an improvement in inflammatory status. (AU) | |
| Processo FAPESP: | 06/61303-7 - Implantação de centro multidisciplinar de dispensação de medicação de alto custo |
| Beneficiário: | Eloisa Silva Dutra de Oliveira Bonfá |
| Modalidade de apoio: | Auxílio à Pesquisa - Pesquisa em Políticas Públicas para o SUS |